Head-to-head comparison
Gala Health vs NowPatient
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
A women's desk that pairs a genuine brand-name Ozempic path with low compounded pricing in all 50 states — every rate of which is a yearly subscription.
$1,299/mo (brand-name) sema · $179/mo (see conditions) tirz · Verified August 2026
Marked down on: No month-to-month price is published anywhere — the $179/mo hero now reads “$179/mo all doses, no hidden fees” and the term has moved into a shared footnote under the treatment cards (“Price calculated based on a yearly subscription plan”), the $149/mo microdose tier carries the same term, and the FAQ quotes a third figure at “starting at just $199 per month (with a 3-month plan)”
Desk Score
NowPatient is a US-UK telehealth platform offering brand-name GLP-1 weight management access including Mounjaro, Wegovy (injection and oral tablet), and Saxenda.
$1,349/mo (brand-name) sema · $1,069/mo (brand-name) tirz · Verified July 2026
Marked down on: Cash-pay pricing tracks full brand list price (~$1,000–$1,350/mo)
Gala Health takes this head-to-head with the higher Desk Score, 81/100 (B−) against 59/100 (C) for NowPatient. NowPatient still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
Gala Health
81/100
B−
NowPatient
59/100
C
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | Gala Health | NowPatient |
|---|---|---|
| Semaglutide | $1,299/mobrand-name$1,299/mo (brand Ozempic) | $1,349/mobrand-name$1,349/mo (brand Wegovy) |
| Tirzepatide | $179/mosee conditions$179/mo (compounded GLP-1/GIP containing tirzepatide; the site's own footnote reads “Price calculated based on a yearly subscription plan”; a $149/mo microdose tier carries the same term; no month-to-month rate is published anywhere) | $1,069/mobrand-name$1,069/mo (brand Mounjaro, promotional rate) |
| Coverage | All 50 states | Not listed on NowPatient's site (checked July 2026) |
| Brand-name | Yes | Yes |
| Oral option | Injectable only | Yes |
| Best for | Women ready to commit to a year up front, who want a low compounded rate with a real brand-name Ozempic option on the same account. | Brand-name GLP-1 access without a compounded route. |
| Desk Score | 81/100B− | 59/100C |
The verdict
Desk pick — Gala HealthGala Health takes this head-to-head with the higher Desk Score, 81/100 (B−) against 59/100 (C) for NowPatient. NowPatient still holds its ground where its strengths line up with yours.
Choose Gala Health if…
Women ready to commit to a year up front, who want a low compounded rate with a real brand-name Ozempic option on the same account.
$1,299/mo (brand-name) sema · $179/mo (see conditions) tirz · All 50 states
Choose NowPatient if…
Brand-name GLP-1 access without a compounded route.
$1,349/mo (brand-name) sema · $1,069/mo (brand-name) tirz
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we write about a provider reads the same either way. Read full breakdowns: Gala Health · NowPatient.
Also here
CoreAge Rx leads the whole ranking at 94/100
Whichever of these two you lean toward, our #1-rated provider outscores them both. One price at every dose, both molecules, all 50 states. The $99 and $149 figures are 12-month plans paid up front, not a monthly bill.
More head-to-heads
- CoreAge Rx vs Gala Health
- CoreAge Rx vs NowPatient
- Gala Health vs Ondra Health
- LillyDirect Foundayo vs NowPatient
- Gala Health vs Sesame Care
- Levity vs NowPatient
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.